Last month, the FTC voted unanimously to examine rising list prices of insulin, but also to probe possible anti-competitive practices by PBMs. Proof of the establishment of anti-competitive practices - such as rebate walls - would likely lead to legal action being taken against PBMs.
Subscribe to:
Post Comments (Atom)
< + > Stop Waiting for Interoperability: PocketHealth Uses Agentic AI to Automate Operations Across Systems
Healthcare has spent billions trying to force disparate systems to talk to each other through custom APIs and shared data standards. Yet adm...
No comments:
Post a Comment